| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Quinolin-8-ol sulfate hydrate targets the 20S proteasome, functioning as a proteasome inhibitor. The 20S proteasome is a protein complex that degrades ubiquitinated proteins, playing a key role in cellular protein homeostasis. By inhibiting the proteasome, the compound can affect protein degradation pathways and may have therapeutic potential in the treatment of drug-resistant bacterial and fungal infections. However, its primary applications are as a research reagent and industrial chemical.
|
|---|---|
| ln Vitro |
Quinolin-8-ol sulfate hydrate (2:1:1) is a biochemical reagent that can be utilized in studies pertaining to life sciences as an organic compound or biological material.
In vitro, Quinolin-8-ol sulfate hydrate is a 20S proteasome inhibitor. Its activity is assessed in cell-based and biochemical assays measuring proteasome activity and the accumulation of ubiquitinated proteins. The compound has been studied for its potential in treating drug-resistant bacterial and fungal infections through metal chelation. Detailed in vitro activity data, including IC₅₀ values, may be available in the literature for specific applications. |
| ln Vivo |
Quinolin-8-ol sulfate hydrate may be used in vivo for pharmacological activity assessment in studies of proteasome inhibition and metal chelation. It has been investigated for the treatment of drug-resistant bacterial and fungal infections with metal-chelating compounds. Animal models of infection may be used to evaluate its efficacy. All procedures must comply with institutional animal care and use guidelines.
|
| Enzyme Assay |
In vitro enzyme assays for Quinolin-8-ol sulfate hydrate typically involve measuring its inhibition of 20S proteasome activity. The compound is incubated with purified proteasome or cell lysates, and proteasome activity is measured using fluorogenic or chromogenic substrates. Standard biochemical protocols for proteasome activity assays are employed. The compound's metal-chelating properties can also be assessed using spectroscopic methods.
|
| Cell Assay |
In vitro cell-based assays for Quinolin-8-ol sulfate hydrate utilize cell lines to assess proteasome inhibition and cytotoxicity. Cells are treated with the compound, and proteasome activity is measured using fluorogenic substrates. Cell viability and apoptosis markers are assessed using MTT, Annexin V, or caspase activity assays. Standard cell culture conditions (37°C, 5% CO₂) with appropriate media are employed.
|
| Animal Protocol |
In vivo animal studies with Quinolin-8-ol sulfate hydrate would typically involve administration to animal models of infection or cancer to evaluate its efficacy as a proteasome inhibitor or metal-chelating agent. Endpoints include assessment of infection clearance, tumor growth inhibition, and pharmacokinetic profiling. All procedures must comply with institutional animal care and use guidelines.
|
| ADME/Pharmacokinetics |
Quinolin-8-ol sulfate hydrate has a molecular weight of 406.41 g/mol and a molecular formula of C₁₈H₁₈N₂O₇S. It is a 20S proteasome inhibitor. The compound is used as a dye and as a raw material for chemical analysis. It is typically stored under standard laboratory conditions. It is soluble in water and organic solvents.
|
| Toxicity/Toxicokinetics |
Quinolin-8-ol sulfate hydrate is intended for research use only and is not approved for human therapeutic applications. As a research chemical, comprehensive toxicological data are not extensively documented in the publicly accessible literature. Standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. The compound should be handled in well-ventilated areas with proper waste disposal procedures.
|
| Additional Infomation |
Quinolin-8-ol sulfate hydrate (8-Hydroxyquinoline sulfate hydrate) (CAS#: 207386-91-2) has a molecular formula of C₁₈H₁₈N₂O₇S and a molecular weight of 406.41 g/mol. It is a 20S proteasome inhibitor used as a dye, as a raw material for chemical analysis, and in the treatment of drug-resistant infections. This compound is not a drug and has not undergone clinical trials.
|
| Molecular Formula |
C18H18N2O7S
|
|---|---|
| Molecular Weight |
406.41
|
| Exact Mass |
261.03
|
| CAS # |
207386-91-2
|
| PubChem CID |
2723812
|
| Appearance |
Light yellow to green yellow solid powder
|
| Boiling Point |
267ºC at 760mmHg
|
| Melting Point |
176-179 °C(lit.)
|
| Flash Point |
143.1ºC
|
| Vapour Pressure |
0.00508mmHg at 25°C
|
| LogP |
2.304
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
28
|
| Complexity |
219
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(=O)(=O)(O[H])O[H].O([H])C1=C([H])C([H])=C([H])C2C([H])=C([H])C([H])=NC=21.O([H])C1=C([H])C([H])=C([H])C2C([H])=C([H])C([H])=NC=21.O([H])[H]
|
| InChi Key |
BNCXJZDIJIVJJO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/2C9H7NO.H2O4S.H2O/c2*11-8-5-1-3-7-4-2-6-10-9(7)8;1-5(2,3)4;/h2*1-6,11H;(H2,1,2,3,4);1H2
|
| Chemical Name |
quinolin-8-ol;sulfuric acid;hydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4606 mL | 12.3028 mL | 24.6057 mL | |
| 5 mM | 0.4921 mL | 2.4606 mL | 4.9211 mL | |
| 10 mM | 0.2461 mL | 1.2303 mL | 2.4606 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
